	US 11,939,391 B2
	Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
Mason Lu, Fremont, CA (US); and Qinhong Ma, Fremont, CA (US)
Assigned to MEDABOME, INC., Fremont, CA (US)
Filed by MedAbome, Inc., Fremont, CA (US)
Filed on Dec. 6, 2021, as Appl. No. 17/542,948.
Prior Publication US 2023/0174663 A1, Jun. 8, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01)

CPC C07K 16/2896 (2013.01) [A61K 35/17 (2013.01); C07K 16/2863 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)]

19 Claims

1. A binding agent targeting TfR1 including a light chain variable region wherein CDR1 to CDR3 have sequences identical to, respectively, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, and a heavy chain variable region wherein CDR1 to CDR3 have sequences identical to, respectively, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.